open access

Vol 89, No 1 (2018)
Research paper
Published online: 2018-01-31
Get Citation

Neuropilin 1 in uterine leiomyosarcoma. Clinical and pathological analysis

Marcin Bobiński1, Karolina Okła1, Jan Kotarski1, Justyna Szumiło2, Grzegorz Polak1, Małgorzata Sobstyl1, Wiesława Bednarek1
DOI: 10.5603/GP.a2018.0002
·
Pubmed: 29411340
·
Ginekol Pol 2018;89(1):7-12.
Affiliations
  1. I Chair and Department Of Gynaecological Oncology and Gynaecology Medical University in Lublin, Poland
  2. Chair and Department of Clinical Pathomorphology, Medical University in Lublin, Poland, Poland

open access

Vol 89, No 1 (2018)
ORIGINAL PAPERS Gynecology
Published online: 2018-01-31

Abstract

Objectives: The role of angiogenesis in leiomyosarcomas still remains unclear. The aim of this study was to evaluate the NRP1 expression in the leiomyosarcoma tissues and to find the relations between its expression and the clinical features.

Material and methods: The study group consisted of 50 patients with diagnosis of the uterine leiomyosarcoma. Clinical and follow up data were collected. Using immunohistochemical methods the expression of NRP1 was detected.

Results: The lack of NRP1 expression was found in 14 cases, positive (weak or moderate) expression was noted in 36 cases. The significantly higher expression of NRP1 was observed in more severe clinical stages in comparison to lower stages of the disease. The significantly shorter survival of patients with the positive expression of NRP1 in leiomyosarcoma was observed.

Conclusions: The expression of NRP1 is associated with clinical advancement and worse prognosis in uterine LMS. Neuropilin 1 can be widely used as a postoperative survival predictor for the patients suffering from uterine LMS.

Abstract

Objectives: The role of angiogenesis in leiomyosarcomas still remains unclear. The aim of this study was to evaluate the NRP1 expression in the leiomyosarcoma tissues and to find the relations between its expression and the clinical features.

Material and methods: The study group consisted of 50 patients with diagnosis of the uterine leiomyosarcoma. Clinical and follow up data were collected. Using immunohistochemical methods the expression of NRP1 was detected.

Results: The lack of NRP1 expression was found in 14 cases, positive (weak or moderate) expression was noted in 36 cases. The significantly higher expression of NRP1 was observed in more severe clinical stages in comparison to lower stages of the disease. The significantly shorter survival of patients with the positive expression of NRP1 in leiomyosarcoma was observed.

Conclusions: The expression of NRP1 is associated with clinical advancement and worse prognosis in uterine LMS. Neuropilin 1 can be widely used as a postoperative survival predictor for the patients suffering from uterine LMS.

Get Citation

Keywords

uterine sarcoma, neuropilin 1, angiogenesis

About this article
Title

Neuropilin 1 in uterine leiomyosarcoma. Clinical and pathological analysis

Journal

Ginekologia Polska

Issue

Vol 89, No 1 (2018)

Article type

Research paper

Pages

7-12

Published online

2018-01-31

DOI

10.5603/GP.a2018.0002

Pubmed

29411340

Bibliographic record

Ginekol Pol 2018;89(1):7-12.

Keywords

uterine sarcoma
neuropilin 1
angiogenesis

Authors

Marcin Bobiński
Karolina Okła
Jan Kotarski
Justyna Szumiło
Grzegorz Polak
Małgorzata Sobstyl
Wiesława Bednarek

References (25)
  1. Bodner K, Bodner-Adler B, Kimberger O, et al. Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study. J Reprod Med. 2003; 48(2): 95–100.
  2. Ramondetta L, Bodurka D, Deavers M, et al. Uterine Sarcomas. Gynecologic Cancer. 2006: 125–147.
  3. Ueda SM, Kapp DS, Cheung MK, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol. 2008; 198(2): 218.e1–218.e6.
  4. Wang Y, Yao X, Ge J, et al. Can vascular endothelial growth factor and microvessel density be used as prognostic biomarkers for colorectal cancer? A systematic review and meta-analysis. ScientificWorldJournal. 2014; 2014: 102736.
  5. Li S, Li Q. Cancer stem cells, lymphangiogenesis, and lymphatic metastasis. Cancer Lett. 2015; 357(2): 438–447.
  6. He Y, Rajantie I, Pajusola K, et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005; 65(11): 4739–4746.
  7. Tezuka K, Onoda N, Takashima T, et al. Prognostic significance of lymphovascular invasion diagnosed by lymphatic endothelium immunostaining in breast cancer patients. Oncol Rep. 2007; 17(5): 997–1003.
  8. Nasarre P, Gemmill RM, Drabkin HA. The emerging role of class-3 semaphorins and their neuropilin receptors in oncology. Onco Targets Ther. 2014; 7: 1663–1687.
  9. Shahrabi-Farahani S, Wang L, Zwaans BMM, et al. Neuropilin 1 expression correlates with differentiation status of epidermal cells and cutaneous squamous cell carcinomas. Lab Invest. 2014; 94(7): 752–765.
  10. Handa A, Tokunaga T, Tsuchida T, et al. Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma. Int J Oncol. 2000; 17(2): 291–295.
  11. Fakhari M, Pullirsch D, Abraham D, et al. Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and -2 in human neuroblastoma. Cancer. 2002; 94(1): 258–263.
  12. Osada H, Tokunaga T, Nishi M, et al. Overexpression of the neuropilin 1 (NRP1) gene correlated with poor prognosis in human glioma. Anticancer Res. 2004; 24(2B): 547–552.
  13. Kawakami T, Tokunaga T, Hatanaka H, et al. Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer. 2002; 95(10): 2196–2201.
  14. Rossignol M, Beggs AH, Pierce EA, et al. Human neuropilin-1 and neuropilin-2 map to 10p12 and 2q34, respectively. Genomics. 1999; 57(3): 459–460.
  15. Wild JRL, Staton CA, Chapple K, et al. Neuropilins: expression and roles in the epithelium. Int J Exp Pathol. 2012; 93(2): 81–103.
  16. Bednarek W, Mazurek-Kociubowska M, Sobstyl M, et al. Expression of lymphangiogenesis marker neuropilin-1 in different types of ovarian cancer. Ginekol Pol. 2010; 81(3): 176–182.
  17. Kärpänen T, Heckman CA, Keskitalo S, et al. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J. 2006; 20(9): 1462–1472.
  18. Xu Y, Yuan Li, Mak J, et al. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol. 2010; 188(1): 115–130.
  19. FIGO staging for uterine sarcomas. International Journal of Gynecology & Obstetrics. 2009; 104(3): 179.
  20. de Oliveira AT, Pinheiro C, Longatto-Filho A, et al. Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs). J Bioenerg Biomembr. 2012; 44(1): 171–178.
  21. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008; 112(4): 820–830.
  22. Roth L. The good, the bad and the ugly: a neuropilin-2 story from normal to tumor-associated lymphangiogenesis. Cell Adh Migr. 2008; 2(4): 217–219.
  23. Lu J, Cheng Y, Zhang G, et al. Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma. Mol Med Rep. 2015; 12(2): 2668–2676.
  24. Jiang H, Xi Q, Wang F, et al. Increased expression of neuropilin 1 is associated with epithelial ovarian carcinoma. Mol Med Rep. 2015; 12(2): 2114–2120.
  25. Manjappa AS, Goel PN, Gude RP, et al. Anti-neuropilin 1 antibody Fab' fragment conjugated liposomal docetaxel for active targeting of tumours. J Drug Target. 2014; 22(8): 698–711.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl